Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1628301

	registered interest
	date	16/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Advanced Therapy Medicinal Products
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of reviewing the way the National Institute for Health and Care Excellence and NHS England evaluate and adopt Advanced Therapy Medicinal Products as technologies with the potential to deliver significant health gains over long periods of time.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	185240
	answer	answer is ministerial correction date of answer 25/05/2023 answer text <p>The National Institute of Health and Care Excellence (NICE) recently carried out a comprehensive review of its methods and processes for health technology evaluation to ensure that they were appropriate to emerging new technologies such as advanced therapeutic medicinal products (ATMPs). NICE published its updated health technology evaluation manual in January 2022 and has introduced a number of changes that ensure that its appraisal processes are suitable for emerging new medicines, including a broader severity modifier and changes to better respond to uncertainty. There are no plans for a further assessment of NICE’s processes for evaluating ATMPs.</p><p> </p><p>NICE’s methods and processes have been proven to be suitable for ATMPs where companies are willing to price their products in a way that represents value to the taxpayer. NICE has recommended 80% of the ATMPs it has evaluated for use by the National Health Service and they are now available for the treatment of NHS patients, including through the Cancer Drugs Fund and managed access agreements negotiated between the NHS and the manufacturer.</p> answering member constituency Colchester answering member printed Will Quince question first answered 25/05/2023 12:35:12 answering member 4423 label Biography information for Will Quince
	tabling member	3960 label Biography information for Henry Smith

1671983

	registered interest
	date	21/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase access to bowel cancer screenings.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	2858
	answer	answer is ministerial correction date of answer 27/11/2023 answer text <p>Based on advice from the UK National Screening Committee, the National Health Service is currently extending the age criteria for bowel cancer screening from between 60 and 74 years old so that screening will be available from the age of 50 years old; this is due to be completed by 2024/25. This will increase access for people who would have otherwise not been able to access the service.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/11/2023 16:11:07 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1700141

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve genomics testing for bowel cancer patients.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	20972
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>A National Health Service testing programme is helping to diagnose thousands of people with a genetic condition, Lynch Syndrome, that increases the chance of developing certain cancers including bowel cancer. The national programme ensures all people diagnosed with bowel cancer are offered genomic testing, with a diagnosis for Lynch Syndrome not only helping to guide more personalised cancer treatment but enabling their families and relatives to be offered testing too. Relatives who receive a diagnosis of Lynch Syndrome can be referred to genetic services to discuss regular testing options to help catch any cancers as early as possible, as well as to consider preventive options such as taking aspirin or undergoing risk-reducing surgery.</p><p>Genomic testing in the NHS in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (NGTD) which outlines the full range of genomic testing offered by the NHS in England including tests for 3,200 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used, including testing for bowel cancer patients.</p><p>The NHS GMS cancer genomic testing strategy has facilitated a move to a consolidated laboratory network through the seven NHS GLHs delivering more extensive panel testing using cutting edge high throughput Next Generation Sequencing (NGS) technology. For patients, including those with bowel cancer, this technology enables testing for a larger number of genetic variations to give a more precise diagnosis, identify biomarkers to target treatment and opportunities to access innovative medicines, and can support enrolment into molecularly stratified clinical trials.</p><p>Testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional (for example, their general practitioner or other healthcare professional if they are already being seen in a relevant service) whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS clinical genomics service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.</p><p>The 17 NHS Clinical Genomic Services (NHS CGSs), commissioned by NHS England, deliver a comprehensive clinical genomic and counselling service that directs the diagnosis, risk assessment and lifelong clinical management of patients of all ages and their families who have, or are at risk of having, a rare genetic or genomic condition. As part of the NHS CGS, the patient and their family will access diagnosis, and management relevant to their particular condition, but also receive support and guidance so that they are able to understand their condition, its implications, and their options in relation to reproduction, screening, prevention and clinical management.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 13:43:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1643069

	registered interest
	date	08/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer and Radiology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has made recent representations made to (a) the Chancellor of the Exchequer and (b) NHS England on investment in the clinical (i) radiology and (ii) oncology workforce.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	188505
	answer	answer is ministerial correction date of answer 14/06/2023 answer text <p>The Secretary of State for Health and Social Care meets regularly with other Cabinet colleagues and with NHS England to discuss issues relating to the National Health Service workforce.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 14/06/2023 14:00:35 answering member 4527 label Biography information for Helen Whately
	tabling member	3960 label Biography information for Henry Smith

1691572

	registered interest
	date	26/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cardiovascular Diseases: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help encourage research into cardiovascular disease (a) treatment and (b) prevention.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	15618
	answer	answer is ministerial correction date of answer 04/03/2024 answer text <p>The Department funds research into the treatment and prevention of cardiovascular disease through the National Institute for Health and Care Research (NIHR). In January 2023, the Department updated its areas of research interest (ARIs), which highlight to the patient, academic, clinical and life sciences community the areas where we want to expand our efforts and work together to systematically understand, intervene and improve public, patient, and service outcomes. ARI1 focuses on prevention, early diagnosis and appropriate intervention for people at increased risk of poor health, including cardiovascular disease. Supporting ARI1, the three NIHR Research Schools were awarded £10 million to deliver a collaborative programme of prevention research between 2023 and 2027. The programme will have a strong emphasis on capacity building. It will also encourage practitioners to participate in prevention research as a step towards establishing their own longer-term research careers and help address gaps between research and practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 04/03/2024 15:42:10 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1678334

	registered interest
	date	15/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	DNA: Databases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure the security of DNA data held by (a) the NHS Genomic Medicine Service and (b) private providers of NHS healthcare; and whether she has had discussions with Cabinet colleagues on the potential for cyber attacks by foreign state-linked companies.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	7190
	answer	answer is ministerial correction date of answer 19/12/2023 answer text <p>Organisations which hold sensitive biological data are subject to the UK General Data Protection Regulation. In addition, organisations such as Genomics England, UK Biobank and NIHR BioResource actively consider national security in decision making about partnerships with companies overseas.</p><p>As part of the new UK Biological Security Strategy, the Government is undertaking a programme of work to assess how we can minimise the risks from biological data to protect our burgeoning bioeconomy, without stifling innovation, and build confidence in sharing personal data to improve health outcomes in the United Kingdom and across the world. The Office for Life Sciences has begun this work, in consultation with relevant Departments and Agencies across Government, and key partners such as Genomics England and UK Biobank.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/12/2023 16:10:23 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith

1655923

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Defibrillators
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce economic barriers to accessing defibrillators.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	196006
	answer	answer is ministerial correction date of answer 06/09/2023 answer text <p>The Government has agreed to provide funding of £1 million to design a grant scheme for the expansion of automated external defibrillators (AEDs) that expands the number and accessibility of publicly supported access to defibrillators.</p><p>Applicants will be asked to demonstrate that defibrillators will be placed in areas where they are most needed, such as places with high footfall, longer emergency medical response times and deprived areas</p><p><br> No assessment has been made of the potential fiscal impact of increasing the number of AEDs available to the public on healthcare services. The number of instances of sudden cardiac arrest that have occurred outside of hospitals in the last five years is not available centrally.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196007 196008 question first answered 06/09/2023 15:51:09 answering member 4423 label Biography information for Will Quince
	tabling member	3960 label Biography information for Henry Smith

1655924

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Defibrillators
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential fiscal impact of increasing the number of Automated External Defibrillators available to the public on healthcare services.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	196007
	answer	answer is ministerial correction date of answer 06/09/2023 answer text <p>The Government has agreed to provide funding of £1 million to design a grant scheme for the expansion of automated external defibrillators (AEDs) that expands the number and accessibility of publicly supported access to defibrillators.</p><p>Applicants will be asked to demonstrate that defibrillators will be placed in areas where they are most needed, such as places with high footfall, longer emergency medical response times and deprived areas</p><p><br> No assessment has been made of the potential fiscal impact of increasing the number of AEDs available to the public on healthcare services. The number of instances of sudden cardiac arrest that have occurred outside of hospitals in the last five years is not available centrally.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 196006 196008 question first answered 06/09/2023 15:51:09 answering member 4423 label Biography information for Will Quince
	tabling member	3960 label Biography information for Henry Smith

1671746

	registered interest
	date	21/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services and Social Services: Disability
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has made an assessment of the levels of compliance by health and social care providers with the Accessible Information Standard.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	2857
	answer	answer is ministerial correction date of answer 01/12/2023 answer text <p>National Health Service organisations and publicly funded social care providers must comply with the Accessible Information Standard (AIS) to meet the communication needs of patients and carers with a disability, impairment, or sensory loss. NHS England has completed a review of the AIS to help ensure that everyone’s communication needs are met in health and care provision. The review considered the effectiveness of the current AIS, how the standard is implemented and enforced in practice, and identified recommendations for improvement.</p><p>One of the aims of the review was to strengthen assurance of implementation of the AIS, and a self-assessment framework has been developed to support providers of NHS and social care services to measure their performance against the AIS and develop improvement action plans to address gaps in implementation. The self-assessment framework has also been designed to help the Care Quality Commission (CQC) to gain insight into people's experiences and whether their accessible communication needs are being met, and help CQC better understand organisational performance and to include that in the CQC assessment framework for provider organisations.</p><p>Following publication of the revised standard, NHS England will continue work to support its implementation with awareness raising, communication and engagement and updated e-learning modules on the AIS to ensure NHS staff are better aware of the standard and their roles and responsibilities in implementing it.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 01/12/2023 13:33:09 answering member 4492 label Biography information for Maria Caulfield
	tabling member	3960 label Biography information for Henry Smith

1678211

	registered interest
	date	14/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Trade Competitiveness
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to protect (a) Bupa, (b) HCA Healthcare and (c) other major private healthcare providers from (i) BGI Group and (ii) MGI Tech.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	7019
	answer	answer is ministerial correction date of answer 19/12/2023 answer text <p>Organisations which hold sensitive biological data are subject to the UK General Data Protection Regulation (GDPR). In addition, organisations such as Genomics England, UK Biobank and NIHR BioResource actively consider national security in decision making about partnerships with companies overseas.</p><p>As part of the new UK Biological Security Strategy, the Government is undertaking a programme of work to assess how we can minimise the risks from biological data to protect our burgeoning bioeconomy, without stifling innovation, and build confidence in sharing personal data to improve health outcomes in the United Kingdom and across the world. The Office for Life Sciences has begun this work, in consultation with relevant Departments and Agencies across Government, and key partners such as Genomics England and UK Biobank.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/12/2023 16:02:28 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3960 label Biography information for Henry Smith